Evidence map›Paper›PMID 40441920›Full record

ReviewTrends in biotechnology2025

Scaling DNA engineering.

Weiyi Li, Po-Hsiang Hung, Takeshi Matsui, Sasha F Levy, Gavin Sherlock

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthetic Regulatory Genomics.Annual review of genomics and human genetics · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiyi LiDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Po-Hsiang HungBacStitch DNA Inc., Los Altos, CA, USA.
Takeshi MatsuiBacStitch DNA Inc., Los Altos, CA, USA.
Sasha F LevyBacStitch DNA Inc., Los Altos, CA, USA.
Gavin SherlockDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: gsherloc@stanford.edu.

Funding

Multisizer 4e - equipment for "Fitness Effects of Beneficial Mutations"R35GM131824 · NIGMS · STANFORD UNIVERSITY · PI Gavin J Sherlock · 2019 to 2026
$3.6M
Multiplexed In Vivo DNA AssemblyR01HG011676 · NHGRI · STANFORD UNIVERSITY · PI LEVY, SASHA F · 2022 to 2024
$2.9M
NHGRI NIH HHS R01 HG011676NIGMS NIH HHS R35 GM131824
6 · The paper itself

Abstract

DNA can be engineered to produce new biologics, gene therapies, and cellular therapies, and to reprogram organisms. Having the ability to engineer DNA at scale can accelerate the development of these applications. Existing technologies excel at short oligonucleotide synthesis by chemical or enzymatic methods (up to 2000 bp) and intermediate-size DNA assembly (up to 5-7 kb). Yet synthesizing sequence-validated longer DNA (>10 kb) and/or constructing highly complex combinatorial DNA libraries at scale remains a significant challenge, due largely to technical and cost barriers. Inspired by recent studies on an in vivo DNA processing platform for megabase-long DNA assembly and on high-throughput sequence verification, we discuss how these platforms may be used to achieve DNA engineering at scale.

Indexed as

DNAGenetic EngineeringGene LibraryHumansDNAbacterial conjugationDNA assemblyhomologous recombination

Identifiers

PMID40441920
PMCPMC12360497

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.